Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IOBT NASDAQ:KOOL NASDAQ:ONCY NASDAQ:THMO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIOBTIO Biotech$2.05+2.5%$1.38$0.66▼$2.14$131.76M0.36300,467 shs754,365 shsKOOLCesca Therapeutics$11.94+0.3%$2.78$2.10▼$7.00$28.85M1.07112,188 shs34,264 shsONCYOncolytics Biotech$1.27-3.8%$0.68$0.33▼$1.53$119.74M1.07739,146 shs1.19 million shsTHMOThermoGenesis$0.00$0.00▼$0.60$1K1.175,900 shsN/ATen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIOBTIO Biotech+2.50%+39.46%+57.69%+138.34%+55.30%KOOLCesca Therapeutics+0.61%+0.20%+4.94%+23.24%+11.44%ONCYOncolytics Biotech-3.79%+7.63%+71.62%+126.38%+19.82%THMOThermoGenesis0.00%0.00%0.00%-66.67%-99.93%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIOBTIO Biotech3.672 of 5 stars3.75.00.00.02.82.50.6KOOLCesca TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AONCYOncolytics Biotech1.3361 of 5 stars3.43.00.00.00.60.00.0THMOThermoGenesisN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIOBTIO Biotech 3.33Buy$9.33355.28% UpsideKOOLCesca Therapeutics 0.00N/AN/AN/AONCYOncolytics Biotech 2.75Moderate Buy$4.33241.21% UpsideTHMOThermoGenesis 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest KOOL, THMO, ONCY, and IOBT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/16/2025ONCYOncolytics BiotechJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/14/2025IOBTIO BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIOBTIO BiotechN/AN/AN/AN/A$0.71 per shareN/AKOOLCesca Therapeutics$9.67M2.98N/AN/A$3.11 per share3.84ONCYOncolytics BiotechN/AN/AN/AN/A$0.05 per shareN/ATHMOThermoGenesis$9.61M0.00N/AN/A($0.99) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIOBTIO Biotech-$95.49M-$1.49N/AN/AN/AN/A-162.55%-125.08%8/12/2025 (Estimated)KOOLCesca Therapeutics-$39.72M-$3.60N/A1,194.09N/A-98.84%-77.30%-37.75%N/AONCYOncolytics Biotech-$23.14M-$0.29N/AN/AN/AN/A-313.77%-130.19%7/30/2025 (Estimated)THMOThermoGenesis-$17.98M-$5.14N/AN/AN/AN/AN/AN/AN/ALatest KOOL, THMO, ONCY, and IOBT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025IOBTIO Biotech-$0.35N/AN/AN/AN/AN/A8/7/2025Q2 2025ONCYOncolytics Biotech-$0.10N/AN/AN/AN/AN/A5/14/2025Q1 2025ONCYOncolytics Biotech-$0.09-$0.06+$0.03-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIOBTIO BiotechN/AN/AN/AN/AN/AKOOLCesca TherapeuticsN/A0.50%N/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ATHMOThermoGenesisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIOBTIO BiotechN/A2.322.32KOOLCesca Therapeutics0.501.520.91ONCYOncolytics BiotechN/A3.203.20THMOThermoGenesisN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIOBTIO Biotech54.76%KOOLCesca Therapeutics3.11%ONCYOncolytics Biotech6.82%THMOThermoGenesis5.78%Insider OwnershipCompanyInsider OwnershipIOBTIO Biotech4.80%KOOLCesca Therapeutics68.90%ONCYOncolytics Biotech0.10%THMOThermoGenesis78.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIOBTIO Biotech3065.88 million62.72 millionNot OptionableKOOLCesca Therapeutics532.42 millionN/ANot OptionableONCYOncolytics Biotech3094.28 million94.19 millionNot OptionableTHMOThermoGenesis407.95 million1.75 millionNot OptionableKOOL, THMO, ONCY, and IOBT HeadlinesRecent News About These CompaniesThe Ice Water Hack: How Aqua Sculpt Boosts Thermogenesis for Fat LossMarch 10, 2025 | globenewswire.comIce Water Hack: How Aqua Sculpt Improves Thermogenesis for Weight LossFebruary 20, 2025 | globenewswire.comNorth American Morning Briefing: Stock Futures, -2-September 19, 2024 | morningstar.comMIs Thermogenesis Holdings Inc Stock (THMO) a Good Investment?August 8, 2024 | aaii.comAThermoGenesis Holdings (OTC:THMO) Stock Quotes, Forecast and News SummaryJuly 28, 2024 | benzinga.comThermoGenesis Holdings (OTC:THMO) Stock, Short Interest ReportJuly 28, 2024 | benzinga.comWhy Is ThermoGenesis (THMO) Stock Down 37% Today?June 12, 2024 | investorplace.comTHMO Stock Earnings: ThermoGenesis Holdings Misses EPS, Misses Revenue for Q1 2024May 17, 2024 | investorplace.comThermoGenesis Holdings, Inc. (NASDAQ:THMO) Is About To Turn The CornerFebruary 27, 2024 | finance.yahoo.comThermoGenesis Holdings, Inc.January 9, 2024 | thestreet.comThermoGenesis Holdings Stock (NASDAQ:THMO) Dividends: History, Yield and DatesDecember 16, 2023 | benzinga.comShareholders Will Probably Hold Off On Increasing ThermoGenesis Holdings, Inc.'s (NASDAQ:THMO) CEO Compensation For The Time BeingDecember 8, 2023 | finance.yahoo.comThermoGenesis Holdings Recent Insider ActivityNovember 21, 2023 | benzinga.comThermoGenesis Holdings, Inc.: ThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 15, 2023 | finanznachrichten.deThermoGenesis Holdings, Inc. (NASDAQ:THMO) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | finance.yahoo.comThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 13, 2023 | finance.yahoo.comThermoGenesis Q3 Earnings PreviewNovember 12, 2023 | msn.comHere's what Wall Street expects from ThermoGenesis's earnings reportNovember 12, 2023 | markets.businessinsider.comThermoGenesis Holdings Inc THMONovember 12, 2023 | morningstar.comMThermoGenesis Holdings Earnings PreviewNovember 10, 2023 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKOOL, THMO, ONCY, and IOBT Company DescriptionsIO Biotech NASDAQ:IOBT$2.05 +0.05 (+2.50%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$2.04 0.00 (-0.24%) As of 07/18/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.Cesca Therapeutics NASDAQ:KOOLCesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. It offers AutoXpress System, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood; Point-of-CareXpress System, a proprietary automated device and companion sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; CAR-TXpress System, a suite of multi-component automated system that allows the automated manufacturing, expansion, and storage of cellular therapies for immuno-oncology; BioArchive System, an automated cryogenic device for single-cassette based cryo-storage of biological license applications products; and manual bag sets for use in the processing and cryogenic storage of cord blood. The company is also developing autologous stem cell-based therapies that address medical needs for applications in the vascular, cardiology, and orthopedic markets. In addition, it provides cell manufacturing and banking services. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California. Cesca Therapeutics Inc. is a subsidiary of Boyalife (Hong Kong) Limited.Oncolytics Biotech NASDAQ:ONCY$1.27 -0.05 (-3.79%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.27 +0.00 (+0.39%) As of 07/18/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.ThermoGenesis NASDAQ:THMOThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company's point-of-care applications include XP Point-of-Care System, an automated, fully closed, sterile system that allows for the rapid and automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and PXP-1000 System, an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. Its cell processing products comprise X-Series products for general laboratory use, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The company also provides contract development and manufacturing services for cell and cell-based gene therapies. It markets and sells its medical device products through independent distributors, as well as direct to end-user customers. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
